1.72

1.15% -0.02

Engene Therapeutics Inc (ENGN)

Overview News Price History Financials Discussions Forecast

Engene Therapeutics Inc stock is traded at $1.72, with a volume of 885.18K. It is down -1.15% in the last 24 hours and up +9.55% over the past month. enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Previous Close:

$1.74

Open:

$1.75

24h Volume:

885.18K

Relative Volume:

0.57

Market Cap:

$115.22M

Revenue:

Net Income/Loss:

$-122.44M

P/E Ratio:

-0.7631

EPS:

-2.254

Net Cash Flow:

$-103.79M

1W Performance:

+4.88%

1M Performance:

+9.55%

6M Performance:

-78.95%

1Y Performance:

-47.72%

1-Day Range:

$1.695

$1.81

1-Week Range:

$1.62

$1.82

52-Week Range:

$1.40

$12.25

Engene Therapeutics Inc Stock (ENGN) Company Profile

Name

Engene Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

(514) 332-4888

Address

4868 RUE LEVY, SUITE 220, SAINT-LAURENT

Employee

Twitter

Next Earnings Date

2026-06-11

Latest SEC Filings

ENGN's Discussions on Twitter

Compare ENGN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENGN Engene Therapeutics Inc	1.72	115.22M	0	-122.44M	-103.79M	-2.254
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	WBB Securities	Buy
Jan-30-26	Initiated	Jefferies	Buy
Nov-11-25	Upgrade	Raymond James	Outperform → Strong Buy
Feb-18-25	Initiated	Piper Sandler	Overweight
Feb-14-25	Downgrade	UBS	Buy → Neutral
Dec-23-24	Initiated	H.C. Wainwright	Buy
Nov-27-24	Initiated	Raymond James	Outperform
Nov-18-24	Initiated	JMP Securities	Mkt Outperform
Aug-28-24	Initiated	Oppenheimer	Outperform
Apr-22-24	Initiated	Wells Fargo	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Mar-28-24	Initiated	UBS	Buy
Mar-08-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	Leerink Partners	Outperform

View All

Engene Therapeutics Inc Stock (ENGN) Latest News

Jun 19, 2026

enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan

Jun 18, 2026

enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape - Streetwise Reports

Jun 18, 2026

EnGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says - marketscreener.com

Jun 18, 2026

Morgan Stanley Downgrades enGene to Underweight From Equalweight - marketscreener.com

Jun 18, 2026

Morgan Stanley cuts Engene stock rating on reduced sales outlook - Investing.com

Jun 18, 2026

Morgan Stanley cuts Engene stock rating on reduced sales outlook By Investing.com - Investing.com UK

Jun 18, 2026

Jun 17, 2026

enGene Therapeutics (ENGN) director awarded options for 31,000 shares - Stock Titan

Jun 17, 2026

enGene Therapeutics (ENGN) grants director 31,000 stock options - Stock Titan

Jun 17, 2026

enGene Therapeutics (ENGN) director receives 31,000 stock options at $1.75 strike - Stock Titan

Jun 17, 2026

[Form 4] enGene Therapeutics Inc. Insider Trading Activity - Stock Titan

Jun 17, 2026

enGene Therapeutics (ENGN) director awarded 31,000 stock options - Stock Titan

Jun 17, 2026

Director Michael Heffernan of enGene (ENGN) awarded options on 31,000 shares - Stock Titan

Jun 17, 2026

Lota S. Zoth granted 31,000 options at enGene Therapeutics (ENGN) - Stock Titan

Jun 17, 2026

enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026

Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV) - The Globe and Mail

Jun 17, 2026

Guggenheim Maintains EnGene Therapeutics(ENGN.US) With Hold Rating - Moomoo

Jun 17, 2026

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail

Jun 17, 2026

EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN

Jun 17, 2026

Jun 16, 2026

EnGene slashes staff by 50% to preserve cash ahead of regulatory push - The Business Journals

Jun 16, 2026

ENGN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Jun 16, 2026

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Jun 16, 2026

H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com - Investing.com Nigeria

Jun 16, 2026

H.C. Wainwright cuts Engene stock price target on clinical setbacks - Investing.com

Jun 16, 2026

Layoff Tracker: Neumora, enGene cut staff in cost-saving initiatives - BioSpace

Jun 16, 2026

Jun 15, 2026

enGene (ENGN) Announces Workforce Reduction and Leadership Changes - GuruFocus

Jun 15, 2026

enGene Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Jun 15, 2026

EnGene Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 - marketscreener.com

Jun 15, 2026

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace

Jun 15, 2026